We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sequana Medical NV (SEQUA) NPV

Sell:€1.46 Buy:€1.52 Change: €0.055 (3.53%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:€1.46
Buy:€1.52
Change: €0.055 (3.53%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:€1.46
Buy:€1.52
Change: €0.055 (3.53%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

Contact details

Address:
Kortrijksesteenweg 1112
Sint-Denijs-Westrem
GENT
9052
Belgium
Telephone:
+32 (9) 2928065
Website:
https://www.sequanamedical.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SEQUA
ISIN:
BE0974340722
Market cap:
€47.18 million
Shares in issue:
30.24 million
Sector:
Health Care Equipment
Exchange:
Euronext Brussels
Country:
Belgium
Currency:
Euro
Indices:
n/a

Key personnel

  • Ian Crosbie
    Chief Executive Officer, Executive Director
  • Kirsten Van Bockstaele
    Chief Financial Officer
  • Dirk Fengels
    Global Vice President Engineering and Manufacturing
  • Timur Resch
    Global Vice President Quality Management and Regulatory Affairs
  • Martijn Blom
    Chief Commercial Officer
  • Gijs Klarenbeek
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.